KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

AbCellera Biologics (ABCL) Operating Income (2020 - 2023)

AbCellera Biologics (ABCL) has disclosed Operating Income for 4 consecutive years, with -$66.1 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Operating Income fell 74.85% year-over-year to -$66.1 million, compared with a TTM value of -$237.2 million through Dec 2023, down 209.56%, and an annual FY2024 reading of -$314.8 million, down 32.7% over the prior year.
  • Operating Income was -$66.1 million for Q4 2023 at AbCellera Biologics, down from -$54.9 million in the prior quarter.
  • Across five years, Operating Income topped out at $225.0 million in Q1 2022 and bottomed at -$66.1 million in Q4 2023.
  • Average Operating Income over 4 years is $21.2 million, with a median of -$4.6 million recorded in 2020.
  • Peak annual rise in Operating Income hit 7549.29% in 2021, while the deepest fall reached 1489.14% in 2021.
  • Year by year, Operating Income stood at $160.8 million in 2020, then plummeted by 49.28% to $81.6 million in 2021, then tumbled by 146.32% to -$37.8 million in 2022, then plummeted by 74.85% to -$66.1 million in 2023.
  • Business Quant data shows Operating Income for ABCL at -$66.1 million in Q4 2023, -$54.9 million in Q3 2023, and -$51.4 million in Q2 2023.